Sanofi reported that its GLP-1, lixisenatide, bested the GLP-1 Byetta, exenatide, in a head to head trial of type 2 diabetes patients. The lixisenatide arm experienced many fewer hypoglycemia events (about 6-fold fewer).
Sanofi's GLP-1 drug when approved will take on Novo Nordisk's Victoza and Amylin/Lilly's Byetta. It's being billed as a blockbuster candidate by many analysts. This is especially true with the world's diabetic population expected to explode from 285 million to more than 435 million in the next 20 years - keep eating that quality Western diet.
Sanofi is playing catch up with its GLP-1 version so this type of result with a putative direct competitor product is a good shot in the arm.
Posted by Bruce Lehr Feb 2nd 2011.
More on this from PBR Clinical Trials
http://clinicaltrials.pharmaceutical-business-review.com/news/sanofi-aventis-phase-iii-study-of-lixisenatide-meets-primary-endpoint-020211
Posted by: bigredbruce | 02/03/2011 at 01:59 PM